Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Hansoh granted Avere exclusive development, manufacturing, and commercialization rights to HS-20118, also called AVR-001, outside Greater China. The oral cyclic IL-23R antagonist agreement includes $120 million in upfront payments, up to $2.18 billion in milestones, and royalties. Avere also announced a proposed NextCure merger. Conditional milestone value and a signed merger agreement do not represent realized payments or closing.
Vilya’s technical preprint describes an all-atom model for conformational sampling and developability prediction across macrocycles with diverse chemistries and noncanonical residues. The framework supports permeability modeling and molecular design within the company’s oral-macrocycle strategy. Computational benchmark performance does not demonstrate human oral bioavailability, efficacy, or safety; the report is a preprint rather than peer-reviewed clinical evidence.
Salubris announced NMPA clinical-trial clearance for SAL0167 tablets for hyperlipidemia and identified the proprietary candidate as a cyclic peptide. The authorization permits clinical development but does not establish human dosing, quantitative oral exposure, or lipid-lowering efficacy. General statements about cyclic-peptide advantages should not be treated as demonstrated properties of this particular candidate.
LG AI Research and D&D Pharmatech signed a master agreement for next-generation oral peptide discovery, explicitly including macrocyclic peptides. The collaboration combines AI design with peptide development expertise. Named candidates, targets, financial terms, and human results were not disclosed. The agreement sets research objectives rather than demonstrating that oral absorption or clinical efficacy challenges have been solved.
Ironwood announced FDA approval of linaclotide for functional constipation in children ages 2 and older, extending the previous indication covering ages 6 and older. A 12-week, placebo-controlled Phase 3 trial in children ages 2–5 supported the decision, with improved spontaneous bowel-movement frequency at 72 micrograms. This concerns a gut-acting oral peptide, rather than systemic peptide delivery.
20n Bio announced $7.5 million in Seed+ financing to advance AI-enabled cyclic peptide discovery, screening workflows, and its therapeutic pipeline. The company identifies oral peptides among potential applications but has not disclosed a validated clinical oral cyclic peptide candidate or human oral pharmacokinetics. The strategic lead investor was unnamed; investors from earlier rounds should not be assigned to this financing.
Hansoh presented two randomized, double-blind, placebo-controlled Phase 1 studies of HS-20118 involving 129 treated participants, including healthy volunteers and 23 patients with psoriasis. The company reported sustained pharmacokinetic and pharmacodynamic activity and early skin-response signals supporting exploration of weekly oral dosing. Small patient cohorts and short treatment duration limit conclusions about comparative efficacy and long-term safety.
Merck announced a Science publication describing large-scale biocatalytic synthesis of enlicitide. Engineered enzymes enable peptide-fragment formation, coupling, and macrocyclization, combined with crystallization-based purification. The work addresses manufacturing of a complex orally available macrocyclic peptide. It provides a process-development example rather than new clinical efficacy evidence or a universally transferable route for every macrocycle.
Haisco disclosed clinical-trial clearance for HSK47388(I) tablets in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, while its psoriasis program was already in Phase 2. The filing describes preclinical effects in rat colitis models, not patient efficacy. This milestone expands authorized clinical development and is not marketing approval or confirmation of therapeutic benefit.
Sunshine Guojian discussed its 629 oral IL-23 cyclic peptide program in an investor-relations record, saying pharmacokinetic findings suggest potential for weekly dosing. The document did not provide study species, participant details, quantitative exposure, or clinical outcomes. These are company development claims and do not establish validated human bioavailability, weekly clinical efficacy, or an approved dosing regimen.
Syneron Bio announced a $150 million Series B financing that closed on March 31. An international life-science fund led the round, with Decheng Capital, CDH VGC, and other investors participating. Proceeds will develop Synova and advance oncology, autoimmune, metabolic, and rare-disease programs toward the clinic. Named candidates, enrollment milestones, and human oral pharmacokinetics were not disclosed.
Triastek announced FDA IND clearance for T25, a modified-release oral octreotide acetate tablet intended for maintenance treatment of adults with acromegaly who respond to somatostatin analogs. The candidate combines MED&SSE printing with its 3D microstructure delivery system. Clearance enables clinical development; the announcement did not provide human pharmacokinetic or efficacy results.
Continue your research
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
